OPK insider Phillip Frost adds 580K OPKO Health shares on 11/20/25
Rhea-AI Filing Summary
OPKO Health (OPK) insider trading report: Phillip Frost, M.D., who serves as CEO, Chairman, director and a 10% owner of OPKO Health, reported a series of open-market purchases of the company’s common stock. On 11/20/2025, he bought a total of 580,000 common shares in multiple trades at prices ranging from $1.32 to $1.35 per share, all reported as indirect ownership through Frost Gamma Investments Trust. After these transactions, one reported indirect position shows 216,126,448 shares beneficially owned. The filing also lists 3,568,951 shares held directly and an additional 30,127,177 shares held indirectly through Frost Nevada Investments Trust. The report states that beneficial ownership is disclaimed except to the extent of any pecuniary interest.
Positive
- None.
Negative
- None.
Insights
CEO/Chairman and 10% owner increased indirect stake via open-market purchases on
The filing shows multiple open-market purchases of **Common Stock** on
These shares are held through a layered trust and partnership structure (Frost Gamma Investments Trust and related entities), and the reporting person expressly disclaims beneficial ownership beyond any economic interest. Another block of **3,568,951** shares is listed as directly owned, and **30,127,177** shares as indirectly owned through a separate Frost Nevada structure, also with a similar ownership disclaimer. The person remains a **Director**, **CEO & Chairman**, and **10% Owner**, so this activity relates to an already large, influential stake.
Insider open-market purchases by a senior control figure often align with a constructive view of their economic exposure, though no motive is stated. The key concrete items to monitor from this disclosure are the increased indirect position to **216,126,448** shares as of
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 119,129 | $1.32 | $157K |
| Purchase | Common Stock | 47,105 | $1.325 | $62K |
| Purchase | Common Stock | 211,948 | $1.33 | $282K |
| Purchase | Common Stock | 161,818 | $1.335 | $216K |
| Purchase | Common Stock | 24,579 | $1.34 | $33K |
| Purchase | Common Stock | 1,757 | $1.345 | $2K |
| Purchase | Common Stock | 13,664 | $1.35 | $18K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. These securities are held by Frost Nevada Investments Trust, of which the Reporting Person is the trustee and Frost-Nevada, L.P. is the sole and exclusive beneficiary. The Reporting Person is one of seven limited partners of Frost-Nevada, L.P. and the sole shareholder of Frost-Nevada Corporation, the sole general partner of Frost-Nevada, L.P. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
